Source / episode info

• **Episode:**631
• **Title:**DIP Ep 631-Travel Medicine Part A (super HY with numerous integrations, for Step 1-3)
• **Published:**2026-02-09
• Source:Episode page

One-liner

This episode provides a comprehensive review of high-yield travel medicine topics, emphasizing the mechanisms behind malaria prophylaxis (e.g., primaquine/G6PD), diarrheal pathogens (ETEC secretory vs. GARD malabsorptive), viral hemorrhagic fevers (Dengue ADE), and vaccine safety protocols for immunocompromised patients.

High-yield summary

• Vaccine Timing: Pre-travel vaccines should be administered 2–4 weeks prior to travel to ensure adequate antibody response; multi-dose series require longer spacing.
• Malaria Drugs & Contraindications: Tofolacone/Proguanil is contraindicated in renal failure; Mefloquine is contraindicated in seizure disorders, psychiatric conditions, and cardiac conduction defects.
• Gastroenteritis Differentiation: Giardia causes long-lasting, malabsorptive diarrhea (steatorrhea) due to mucosal damage, while ETEC causes acute, secretory watery diarrhea via toxin activation of cAMP/cAMP pathways.
• Dengue Pathophysiology: Secondary dengue infection with a different serotype can be life-threatening due to Antibody Dependent Enhancement (ADE), where pre-existing antibodies bind the new virus and facilitate entry into immune cells via Fc receptors.
• Yellow Fever: A flavivirus transmitted by Aedes mosquitoes; causes high fever, jaundice, bleeding, and acute kidney injury; vaccine is required for travel to sub-Saharan Africa/Amazon Basin.
• Cryptosporidium Management: In immunocompromised patients (CD4 < 200), treatment requires Nitazoxanide plus Anti-retroviral Therapy (ART) to improve prognosis, as ART restores the T-cell immunity needed for clearance.

Learning objectives

• Differentiate the clinical and pathophysiological presentations of various diarrheal pathogens encountered during travel.
• Explain the mechanism of Antibody Dependent Enhancement in dengue fever, linking it to serotype switching and immune cell receptors.
• Identify key contraindications for antimalarial drugs (e.g., primaquine/G6PD deficiency; mefloquine/cardiac issues).
• Recognize the clinical signs and required vaccinations for flavivirus infections like Yellow Fever.
• Understand the management principles for chronic diarrheal pathogens in immunocompromised hosts, particularly Cryptosporidium.